MMWR Early Release: Morbidity and Mortality Weekly Report, March 11, 2022: Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years -- PROTECT Cohort, July 2021-February 2022 [open pdf - 379KB]
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). [It] is the agency's primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. This Early Release issue of MMWR contains the following article: "Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech [Biopharmaceutical New Technologies]) mRNA [Messenger Ribonucleic Acid] Vaccine in Preventing SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years -- PROTECT [Pediatric Research Observing Trends and Exposures in COVID-19 [coronavirus disease 2019] Timelines] Cohort, July 2021-February 2022." Notifiable Diseases and Mortality Tables from MMWR can be accessed at the following link [http://www.cdc.gov/mmwr/index2022.html].
Morbidity and Mortality Weekly Report: http://www.cdc.gov/mmwr/index.html/
MMWR Early Release: Morbidity and Mortality Weekly Report (March 11, 2022), v.71